{"id":447,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","title":{"rendered":"Signalisation Tirzepatide double GIP\/GLP-1\u00a0: explication du m\u00e9canisme et des param\u00e8tres d'essai"},"content":{"rendered":"
Tirzepatide est un peptide acyl\u00e9 con\u00e7u pour activer \u00e0 la fois le r\u00e9cepteur du polypeptide insulinotrope glucose-d\u00e9pendant (GIP) et le r\u00e9cepteur du peptide de type glucagon-1 (GLP-1). Comprendre que la double pharmacologie n\u00e9cessite de s\u00e9parer l'activit\u00e9 des r\u00e9cepteurs des r\u00e9sultats cliniques mesur\u00e9s dans des populations sp\u00e9cifiques.<\/p>
Points cl\u00e9s \u00e0 retenir<\/h2>
Tirzepatide est un double agoniste des r\u00e9cepteurs GIP\/GLP-1, et non un \u00ab triple agoniste \u00bb.<\/li>
Les essais SURPASS se sont concentr\u00e9s sur les r\u00e9sultats du diab\u00e8te de type 2\u00a0; Les essais SURMOUNT se sont concentr\u00e9s sur les r\u00e9sultats li\u00e9s \u00e0 l'ob\u00e9sit\u00e9.<\/li>
Les donn\u00e9es sur les m\u00e9dicaments finis approuv\u00e9es par FDA n'\u00e9tablissent pas la qualit\u00e9, la s\u00e9curit\u00e9 ou l'efficacit\u00e9 d'un mat\u00e9riel de catalogue d'utilisation de recherche non li\u00e9.<\/li><\/ul><\/div><\/div>Illustration \u00e9ditoriale originale de la recherche sur les peptides multi-r\u00e9cepteurs. Il s\u2019agit d\u2019une sc\u00e8ne de laboratoire conceptuel, pas d\u2019une image de produit ou de traitement.<\/figcaption><\/figure>
Que signifie l'agonisme \u00e0 double r\u00e9cepteur<\/h2>
GIP et GLP-1 sont des syst\u00e8mes de signalisation sensibles aux nutriments avec des actions superpos\u00e9es et distinctes. Tirzepatide a \u00e9t\u00e9 con\u00e7u comme une mol\u00e9cule capable d\u2019activer les deux r\u00e9cepteurs. L\u2019effet clinique est le r\u00e9sultat de la pharmacologie, de l\u2019exposition et de la formulation de la mol\u00e9cule enti\u00e8re\u00a0; il ne peut pas \u00eatre d\u00e9duit de la simple addition de deux descriptions de parcours distinctes.<\/p>
L'\u00e9tiquette FDA identifie le tirz\u00e9patide comme l'ingr\u00e9dient actif des produits sur ordonnance approuv\u00e9s et d\u00e9crit les indications, les avertissements et les d\u00e9tails de la formulation sp\u00e9cifiques au produit. Ces d\u00e9clarations appartiennent au m\u00e9dicament fini approuv\u00e9 nomm\u00e9 sur l\u2019\u00e9tiquette.<\/p>
Comment lire les programmes d'essai<\/h2>
SURPASS-1 \u00e9tait un essai de phase randomis\u00e9 3 men\u00e9 aupr\u00e8s d'adultes atteints de diab\u00e8te de type 2 insuffisamment contr\u00f4l\u00e9 par l'alimentation et l'exercice. Son crit\u00e8re d'\u00e9valuation principal \u00e9tait la modification de l'h\u00e9moglobine glyqu\u00e9e, le poids corporel et la s\u00e9curit\u00e9 \u00e9tant parmi les crit\u00e8res de jugement suppl\u00e9mentaires. SURMOUNT-1 a recrut\u00e9 des adultes souffrant d'ob\u00e9sit\u00e9 ou de surpoids ainsi que d'une maladie li\u00e9e au poids et a utilis\u00e9 le pourcentage de variation du poids corporel comme crit\u00e8re d'\u00e9valuation principal.<\/p>
La population, le comparateur, la dur\u00e9e du traitement, l'estimation et la gestion de l'arr\u00eat affectent l'interpr\u00e9tation. Un pourcentage global ne doit jamais \u00eatre d\u00e9tach\u00e9 de ces \u00e9l\u00e9ments de conception.<\/p>
SURPASS-1<\/strong>Phase 3, diab\u00e8te de type 2, crit\u00e8re principal de contr\u00f4le glyc\u00e9mique<\/span><\/div>
SURMOUNT-1<\/strong>Phase 3, population ob\u00e8se\/surpoids, crit\u00e8re principal de poids corporel<\/span><\/div>
Dossier r\u00e9glementaire<\/strong>Informations de prescription et langage de s\u00e9curit\u00e9 sp\u00e9cifiques au produit FDA<\/span><\/div><\/div><\/div>
Pourquoi l'\u00e9quivalence mat\u00e9rielle est importante<\/h2>
Les r\u00e9sultats des essais cliniques s\u2019appliquent \u00e0 l\u2019intervention \u00e9tudi\u00e9e, fabriqu\u00e9e et contr\u00f4l\u00e9e dans les conditions de cet essai. L'identit\u00e9 de s\u00e9quence \u00e0 elle seule ne d\u00e9montre pas l'\u00e9quivalence en termes de puret\u00e9, d'agr\u00e9gation, de contre-ion, de st\u00e9rilit\u00e9, de charge particulaire, de formulation ou de stabilit\u00e9.<\/p>
Pour le mat\u00e9riel de recherche sur catalogue, les chercheurs doivent s\u2019appuyer sur les sp\u00e9cifications sp\u00e9cifiques au produit et la documentation du lot. Les all\u00e9gations cliniques d\u2019un m\u00e9dicament approuv\u00e9 ne doivent pas \u00eatre transf\u00e9r\u00e9es vers une page de produit destin\u00e9 \u00e0 la recherche.<\/p>","protected":false},"excerpt":{"rendered":"
Une explication fond\u00e9e sur des preuves de l'agonisme des doubles r\u00e9cepteurs du tirz\u00e9patide et des param\u00e8tres mesur\u00e9s dans les essais SURPASS et SURMOUNT, avec des limites claires sur l'application des donn\u00e9es sur les m\u00e9dicaments aux mat\u00e9riaux du catalogue.<\/p>","protected":false},"author":1,"featured_media":617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"370","pim_article_type":"Clinical evidence explainer","pim_evidence_level":"Randomized phase 3 trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"SURPASS-1 randomized phase 3 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34186022\/\",\"note\":\"Primary clinical trial record; PMID 34186022.\"},{\"title\":\"SURMOUNT-1 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\",\"note\":\"Primary clinical trial record; PMID 35658024.\"},{\"title\":\"FDA prescribing information for Mounjaro (tirzepatide)\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf\",\"note\":\"Approved-finished-product regulatory record.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\" \/>\n<meta property=\"og:description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Signalisation double Tirzepatide GIP\/GLP-1\u00a0: explication du m\u00e9canisme et des param\u00e8tres d'essai - NHD","description":"Une explication fond\u00e9e sur des preuves de l'agonisme des doubles r\u00e9cepteurs du tirz\u00e9patide et des param\u00e8tres mesur\u00e9s dans les essais SURPASS et SURMOUNT, avec des limites claires sur l'application des donn\u00e9es sur les m\u00e9dicaments aux mat\u00e9riaux du catalogue.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_locale":"fr_FR","og_type":"article","og_title":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","og_description":"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.","og_url":"https:\/\/nhdbio.com\/fr\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","url":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","name":"Signalisation double Tirzepatide GIP\/GLP-1\u00a0: explication du m\u00e9canisme et des param\u00e8tres d'essai - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Une explication fond\u00e9e sur des preuves de l'agonisme des doubles r\u00e9cepteurs du tirz\u00e9patide et des param\u00e8tres mesur\u00e9s dans les essais SURPASS et SURMOUNT, avec des limites claires sur l'application des donn\u00e9es sur les m\u00e9dicaments aux mat\u00e9riaux du catalogue.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=447"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/447\/revisions"}],"predecessor-version":[{"id":524,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/447\/revisions\/524"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Chercheur](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")